NTLA241018C45000
- 3.46
- 0.000.00%
Intellia Therapeutics Newsroom
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 10% This Week, Taking Three-year Losses to 86%
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
Buy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data Presentation
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$92m Drop Adds to Long-term Losses
Intellia Therapeutics to Present New Clinical Data From the Phase 1 Study of Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
Intellia Therapeutics: A Bullish Outlook on Gene Editing Innovation and Market Potential
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Is Maintained at Buy by Stifel
Express News | Intellia Therapeutics Inc : Stifel Cuts Target Price to $64 From $80
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Latest 6.7% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Intellia Therapeutics Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)